Comparative Pharmacology
Head-to-head clinical analysis: ACTRON versus COXANTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTRON versus COXANTO.
ACTRON vs COXANTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
1 g intravenous every 6 hours.
None Documented
None Documented
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
NSAID
NSAID